In July, Leach was tapped to take the CEO role permanently at the start of 2026 as part of Dexcom’s planned succession ...
Mike Kratky, an analyst from Leerink Partners, reiterated the Buy rating on Dexcom (DXCM – Research Report). The associated price target was lowered to $87.00. Mike Kratky’s rating is based on ...
Matthew Taylor, an analyst from Jefferies, reiterated the Buy rating on Dexcom (DXCM – Research Report). The associated price target remains the same with $100.00. Discover outperforming stocks and ...
(COLORADO SPRINGS) — A medical device for diabetes called the Dexcom is facing a national shortage that’s now leaving diabetics in Southern Colorado frustrated. A Dexcom is responsible for monitoring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback